On Monday, United Therapeutics received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 81.
Hone Your Stock-Picking Skills By Focusing On These Factors
This proprietary rating identifies market leadership by showing how a stock's price action over the last 52 weeks compares to that of other stocks on the major indexes.
History reveals that the market's biggest winners tend to have an RS Rating of at least 80 in the early stages of their moves.
While the stock is not near a proper entry right now, see if it manages to form and break out of a proper consolidation.
Earnings growth picked up last quarter from 7% to 10%. But sales fell from 17% to 12%.
United Therapeutics holds the No. 11 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
